주식/증권
➡️ 중립
Compass Pathways Targets 2027 COMP360 Launch as FDA Filing Advances
요약
Compass Pathways (NASDAQ:CMPS) said it remains on track to complete a new drug application for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter of this year, with a potential U.S. launch expected in the first half of 2027. During Canaccord